Carolyn Evan
Overview
Explore the profile of Carolyn Evan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
320
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vicier C, Ravi P, Kwak L, Werner L, Huang Y, Evan C, et al.
Prostate
. 2020 Sep;
81(1):50-57.
PMID: 32986884
Background: Characterization of markers of both immune suppression and activation may provide more prognostic information than assessment of single markers in localized prostate cancer. We therefore sought to determine the...
2.
McGregor B, Zhang L, Gray K, Shaw G, Evan C, Francini E, et al.
Prostate Cancer Prostatic Dis
. 2020 Sep;
24(2):341-348.
PMID: 32884090
Background: In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent...
3.
Hamid A, Gray K, Shaw G, Macconaill L, Evan C, Bernard B, et al.
Eur Urol
. 2018 Dec;
76(1):89-97.
PMID: 30553611
Background: TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may drive more aggressive disease. Objective: To...
4.
Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, et al.
J Urol
. 2015 Jan;
194(1):91-7.
PMID: 25623747
Purpose: We examined differences in outcome in patients with biopsy Gleason score 8 vs 9-10 who received definitive local therapy. Materials And Methods: Using an institutional database we identified a...
5.
Parekh A, Chen M, Graham P, Mahal B, Hirsch A, Nakabayashi M, et al.
Clin Genitourin Cancer
. 2014 Aug;
13(1):e1-6.
PMID: 25103271
Background: The Radiation Therapy Oncology Group 96-01 randomized trial demonstrated the benefit of adding androgen deprivation therapy (ADT) to salvage radiotherapy for an increasing prostate-specific antigen (PSA) after prostatectomy, but...
6.
Sharma J, Gray K, Harshman L, Evan C, Nakabayashi M, Fichorova R, et al.
Prostate
. 2014 Mar;
74(8):820-8.
PMID: 24668612
Background: Chemokines and cytokines have been implicated in progression to castration-resistant prostate cancer (CRPC). Methods: Retrospective data were accessed from 122 men with serum samples drawn at a median of...
7.
Sharma J, Gray K, Evan C, Nakabayashi M, Fichorova R, Rider J, et al.
Prostate
. 2013 Oct;
74(3):225-34.
PMID: 24132762
Background: Insulin-like growth factor (IGF) and adipokines have been implicated in prostate cancer carcinogenesis. Method: Data from 122 men with serum samples drawn within 3 months of starting ADT for...
8.
Pomerantz M, Werner L, Xie W, Regan M, Lee G, Sun T, et al.
Cancer Prev Res (Phila)
. 2011 Mar;
4(5):719-28.
PMID: 21367958
Genome-wide association studies have detected more than 30 inherited prostate cancer risk variants. While clearly associated with risk, their relationship with clinical outcome, particularly prostate cancer-specific mortality, is less well...
9.
Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Daskivich T, et al.
Cancer
. 2007 Feb;
109(6):1090-6.
PMID: 17311345
Background: Bisphosphonates have been used to treat bone metastases in hormone-refractory prostate cancer (HRPC), but certain agents have been associated with renal toxicity. For this observational study, the authors assessed...
10.
Oh W, Hayes J, Evan C, Manola J, George D, Waldron H, et al.
Clin Genitourin Cancer
. 2006 Jul;
5(1):61-6.
PMID: 16859581
Background: In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and...